The Difference Between Silvio and Seliniso

Selinexor and Silvio are the same medicine. Xivio is the brand name of Selinisol's original drug on the domestic market. It is sold overseas under brands such as Xpovio. It is a selective nuclear export inhibitor used as an anti-cancer drug. It blocks the transport of several proteins related to cancer cell growth from the nucleus to the cytoplasm by blocking the action of exportin 1, ultimately arresting the cell cycle and leading to apoptosis. It is the first drug with this mechanism of action.

Selinisol received accelerated approval from the U.S. Food and Drug Administration (FDA) in July 2019 for the treatment of adults with relapsed and refractory multiple myeloma (RRMM) who have received at least four prior therapies and whose disease is resistant to several other treatment modalities, including at least two proteasome inhibitors, at least two immunomodulators, and an anti-CD38 monoclonal antibody. In December 2020, selinexor was approved by the FDA in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.

In clinical trials, it was associated with a high rate of serious side effects, including low platelet counts and low blood sodium levels. The most common side effects include nausea, vomiting, decreased appetite, weight loss, diarrhea, fatigue, thrombocytopenia, anemia, low white blood cell levels, and hyponatremia. The existence of these side effects reminds doctors and patients that they still need to carefully evaluate the balance of risks and benefits when using selinesol.